Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.36 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.33 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10110827 | 1.00 | DPP7 (0.40) | DPP7GABRR1RRM1GSRDPP8 | |
| SCHEMBL12680193 | 1.00 | DPP7 (0.40) | DPP7GABRR1RRM1GSRDPP8 | |
| SCHEMBL12680192 | 0.86 | GSR (0.48) | DPP7GSRDPP8DPP9DPP4 | |
| SCHEMBL18159727 | 0.86 | GSR (0.48) | DPP7GSRDPP8DPP9DPP4 | |
| SCHEMBL10532179 | 0.86 | GSR (0.48) | DPP7GSRDPP8DPP9DPP4 | |
| SCHEMBL13301966 | 0.85 | GSR (0.57) | DPP7GSRDPP8DPP9DPP4 | |
| SCHEMBL12420397 | 0.85 | GSR (0.57) | DPP7GSRDPP8DPP9DPP4 | |
| SCHEMBL12825493 | 0.85 | GSR (0.57) | DPP7GSRDPP8DPP9DPP4 | |
| SCHEMBL10533308 | 0.83 | GSR (0.55) | DPP7GSRDPP8DPP9DPP4 | |
| SCHEMBL23376611 | 0.81 | SLC1A2 (0.42) | DPP7DPP8DPP9DPP4SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957290-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957290-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20160304548-A1 | Derivatives of Amphotericin B | ELION THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304548-A1 | Derivatives of Amphotericin B | C9, ERG28, AMPD3 | DPP7 471/4885GABRR1 2211/4885RRM1 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.